BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15534051)

  • 1. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy.
    Tseng J; Dunnwald LK; Schubert EK; Link JM; Minoshima S; Muzi M; Mankoff DA
    J Nucl Med; 2004 Nov; 45(11):1829-37. PubMed ID: 15534051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Charlop A; Lawton TJ; Schubert EK; Tseng J; Livingston RB
    J Nucl Med; 2002 Apr; 43(4):500-9. PubMed ID: 11937594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.
    Mankoff DA; Dunnwald LK; Gralow JR; Ellis GK; Schubert EK; Tseng J; Lawton TJ; Linden HM; Livingston RB
    J Nucl Med; 2003 Nov; 44(11):1806-14. PubMed ID: 14602864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Vrigneaud JM; Kanoun S; Dygai-Cochet I; Berriolo-Riedinger A; Toubeau M; Depardon E; Lassere M; Tisserand S; Fumoleau P; Brunotte F; Cochet A
    J Nucl Med; 2016 Nov; 57(11):1707-1712. PubMed ID: 27103025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.
    Dunnwald LK; Doot RK; Specht JM; Gralow JR; Ellis GK; Livingston RB; Linden HM; Gadi VK; Kurland BF; Schubert EK; Muzi M; Mankoff DA
    Clin Cancer Res; 2011 Apr; 17(8):2400-9. PubMed ID: 21364034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.
    Partridge SC; Vanantwerp RK; Doot RK; Chai X; Kurland BF; Eby PR; Specht JM; Dunnwald LK; Schubert EK; Lehman CD; Mankoff DA
    J Magn Reson Imaging; 2010 Nov; 32(5):1124-31. PubMed ID: 21031518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods.
    Krak NC; van der Hoeven JJ; Hoekstra OS; Twisk JW; van der Wall E; Lammertsma AA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):674-81. PubMed ID: 12640556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer.
    Dunnwald LK; Gralow JR; Ellis GK; Livingston RB; Linden HM; Specht JM; Doot RK; Lawton TJ; Barlow WE; Kurland BF; Schubert EK; Mankoff DA
    J Clin Oncol; 2008 Sep; 26(27):4449-57. PubMed ID: 18626006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D; Chen JH; Wang J; Ling R; Yao Q; Wang L
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.
    Eby PR; Partridge SC; White SW; Doot RK; Dunnwald LK; Schubert EK; Kurland BF; Lehman CD; Mankoff DA
    Acad Radiol; 2008 Oct; 15(10):1246-54. PubMed ID: 18790395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial.
    zum Büschenfelde CM; Herrmann K; Schuster T; Geinitz H; Langer R; Becker K; Ott K; Ebert M; Zimmermann F; Friess H; Schwaiger M; Peschel C; Lordick F; Krause BJ
    J Nucl Med; 2011 Aug; 52(8):1189-96. PubMed ID: 21764790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.
    Kalff V; Duong C; Drummond EG; Matthews JP; Hicks RJ
    J Nucl Med; 2006 Jan; 47(1):14-22. PubMed ID: 16391182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
    J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers.
    Zasadny KR; Tatsumi M; Wahl RL
    Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):274-80. PubMed ID: 12552346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
    Cooper AC; Fleming IN; Phyu SM; Smith TA
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1523-32. PubMed ID: 25579456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis.
    Røe K; Aleksandersen TB; Kristian A; Nilsen LB; Seierstad T; Qu H; Ree AH; Olsen DR; Malinen E
    Acta Oncol; 2010 Oct; 49(7):914-21. PubMed ID: 20831478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study.
    Hentschel M; Paulus T; Mix M; Moser E; Nitzsche EU; Brink I
    Nucl Med Commun; 2007 Oct; 28(10):789-97. PubMed ID: 17728609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.